Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

ZLAB

Zai Lab (ZLAB)

Zai Lab Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ZLAB
일자시간출처헤드라인심볼기업
2024/05/2220:30Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisNASDAQ:ZLABZai Lab Ltd
2024/05/2013:21Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaNASDAQ:ZLABZai Lab Ltd
2024/05/1705:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/05/1620:30Business WireZai Lab Announces Participation in May and June Investor ConferencesNASDAQ:ZLABZai Lab Ltd
2024/05/1605:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/05/1502:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
2024/05/1420:30Business WireZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ZLABZai Lab Ltd
2024/05/1309:20Business WireZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPANASDAQ:ZLABZai Lab Ltd
2024/05/0905:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZLABZai Lab Ltd
2024/05/0905:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
2024/05/0905:05Business WireZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
2024/04/1520:30Business WireZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024NASDAQ:ZLABZai Lab Ltd
2024/04/1120:30Business WireZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesNASDAQ:ZLABZai Lab Ltd
2024/04/0220:30Business WireZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsNASDAQ:ZLABZai Lab Ltd
2024/04/0120:30Business WireZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...NASDAQ:ZLABZai Lab Ltd
2024/03/2722:29Business WireZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:ZLABZai Lab Ltd
2024/03/1408:05Business WireZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsNASDAQ:ZLABZai Lab Ltd
2024/03/0706:01Business WireZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)NASDAQ:ZLABZai Lab Ltd
2024/03/0621:30Business WireZai Lab Announces Participation in March Investor ConferenceNASDAQ:ZLABZai Lab Ltd
2024/03/0506:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/02/2806:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZLABZai Lab Ltd
2024/02/2806:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
2024/02/2806:05Business WireZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
2024/02/0906:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
2024/01/2606:15Business WireZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024NASDAQ:ZLABZai Lab Ltd
2024/01/1107:12Business WireZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLCNASDAQ:ZLABZai Lab Ltd
2024/01/0409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/01/0409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/01/0409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
2024/01/0405:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
 검색 관련기사 보기:NASDAQ:ZLAB

최근 히스토리

Delayed Upgrade Clock